ASX Announcement located, Thanks Buckland 22 December 2023 –...

ASX Announcement located, Thanks Buckland

22 December 2023 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAOA) (“PharmAust” or “the
Company”), a clinical-stage biotechnology company, is pleased to announce that FightMND, Australia’s leading
not-for-profit foundation for Motor Neurone Disease Research has invited PharmAust to submit a full grant
application to help cover costs of its planned Phase 2 study due to begin in H1 2024.

Early this month PharmAust submitted a Letter of Intent to FightMND in response to their call for clinical study
proposals as part of their Phase 2/3 clinical trial and expanded access program for novel, high-potential treatments
in Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS) within the Australian Clinical Trials
Consortium of hospitals. Associate Professor Susan Mathers will be the principal investigator.

The call for clinical study proposals is intended for academic-industry partnerships including but not limited to
pharmaceutical, bio-therapeutic/ biotechnology companies, academic institutions and universities, hospitals, and
MND researchers throughout the world. Up to AUD $1,800,000 in support from FightMND is available per grant.
PharmAust has been notified by FightMND that its Letter of Intent was successfuland invited PharmAust to submit
a full application by the 24th of March 2024. Successful recipients will be notified in July 2024.



So another possible $1.8m in July ,, of non dilutive funding ...